NMN vs NR vs Niacin — Trial Data
NMN, NR, and niacin all raise NAD+ through different biochemical pathways. This page reports the human trial behind each precursor, the one trial that tested three of them head-to-head (Christen et al. 2026), and adverse-event data — each figure attributed to the study that reported it.
On this page
Mechanism
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required by sirtuin enzymes, PARP (DNA-repair) enzymes, and mitochondrial energy metabolism. It is too large to cross cell membranes efficiently when taken orally, so it is raised via smaller precursor molecules instead.
NMN (nicotinamide mononucleotide) is converted to NAD+ by NMNAT enzymes. NR (nicotinamide riboside) enters cells via NRK transporters and converts to NMN, then NAD+. Niacin (nicotinic acid) enters via the Preiss-Handler pathway. Christen et al. 2026 (PMID 41540253) additionally reports, from ex vivo fermentation with human microbiota, that gut bacteria convert NR and NMN into nicotinic acid, and that this microbially-produced nicotinic acid is itself a potent NAD+ booster in whole blood — a proposed gut-dependent mechanism linking all three precursors.
Human Trials, by Precursor
| NMN | NR | Niacin | |
|---|---|---|---|
| Pathway to NAD+ | NMNAT enzymes | NRK (nicotinamide riboside kinase) pathway, then NMN | Preiss-Handler pathway |
| Key human RCT | Yoshino et al. 2021, Science, PMID 33888596 | Martens et al. 2018, Nat Commun, PMID 29599478 | No RCT of niacin specifically as an NAD+ precursor identified for this page |
| Trial population | Postmenopausal women with prediabetes, overweight/obese | Healthy middle-aged and older adults | Not applicable |
| Trial design | 10-week, randomized, double-blind, placebo-controlled | 2×6-week, randomized, double-blind, placebo-controlled, crossover | Not applicable |
| Reported result | Increased insulin-stimulated glucose disposal and skeletal-muscle insulin signaling vs placebo | Well tolerated; elevated whole-blood NAD+ metabolism | Not applicable to this specific comparison |
| Head-to-head evidence | Christen et al. 2026 (PMID 41540253, n=65) — comparably raised NAD+ vs NR | Christen et al. 2026 (PMID 41540253, n=65) — comparably raised NAD+ vs NMN | Not included in the Christen et al. 2026 trial (which compared NMN, NR, and nicotinamide, not niacin) |
| Flush | None reported | None reported | Yes — flushing (warmth, redness, tingling) is a well-documented effect of niacin at therapeutic doses via GPR109A receptor activation |
| Regulatory status | Sold as a dietary supplement in the US; not FDA-approved as a drug | Sold as a dietary supplement in the US; not FDA-approved as a drug | FDA-approved as a prescription drug for dyslipidemia at higher doses; also sold as an over-the-counter supplement |
Yoshino et al. 2021 (Science, PMID 33888596) randomized postmenopausal women with prediabetes who were overweight or obese to 10 weeks of NMN or placebo, double-blind. Insulin-stimulated glucose disposal (hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling increased with NMN and did not change with placebo. The trial did not measure weight loss or longevity outcomes directly.
Martens et al. 2018 (Nat Commun, PMID 29599478) is a randomized, double-blind, placebo-controlled crossover trial (2×6 weeks) of NR in healthy middle-aged and older adults, reporting good tolerability and effective NAD+ metabolism elevation. No randomized controlled trial testing niacin specifically as an NAD+-elevation supplement (as opposed to its established cholesterol-lowering use) has been identified for this page; niacin's role in this comparison rests on the Christen et al. 2026 mechanistic and head-to-head data below.
Head-to-Head: Christen et al. 2026
Christen et al. 2026 (Nat Metab, PMID 41540253, NCT05517122) is the one identified trial that directly compared multiple NAD+ precursors in the same human population. It was a randomized, open-label (not double-blind), placebo-controlled study in 65 healthy participants, comparing 14 days of NR, NMN, or nicotinamide (Nam) against placebo.
Result: NR and NMN comparably increased circulatory NAD+ concentrations over the 14-day course. Nicotinamide did not produce the same sustained increase — it acutely and transiently affected the whole-blood NAD+ metabolome instead. Using ex vivo fermentation with human gut microbiota, the researchers found that NR and NMN give rise to nicotinic acid (niacin) via microbial conversion, and separately showed in whole blood that nicotinic acid, but not NMN, NR, or nicotinamide, is a potent direct NAD+ booster — proposing a gut-dependent mechanism for how NR and NMN raise NAD+.
Niacin (nicotinic acid) itself was not a supplemented arm in this trial — it appears only as the microbially-produced metabolite and as a separate whole-blood experiment. No trial identified for this page directly randomizes human participants to oral niacin against NMN or NR for NAD+ elevation.
Adverse Events
NMN: Yang et al. 2026 (Nutrients, PMID 42514320), a systematic review and meta-analysis of 15 randomized controlled trials (10 contributing safety data; doses 250–2,000 mg/day, durations 14 days to 24 weeks), found NMN did not increase overall, serious, withdrawal-related, or system-specific adverse events, and did not significantly elevate liver enzymes (ALT/AST). No significant effect on body weight, fasting glucose, HbA1c, or lipid profile was observed across the pooled trials.
NR: Martens et al. 2018 reports NR was well tolerated across the trial's two 6-week supplementation periods.
Niacin: flushing (warmth, redness, tingling) is a well-documented effect at therapeutic doses, mediated by GPR109A receptor activation and prostaglandin release; it typically begins 15–30 minutes after dosing and decreases with consistent use as receptors desensitize. At the higher doses used for its FDA-approved cholesterol-lowering indication, niacin carries a documented risk of liver-enzyme elevation, particularly with extended-release formulations.
Evidence Level
NMN: Human RCT (Yoshino et al. 2021, PMID 33888596, double-blind). NR: Human RCT (Martens et al. 2018, PMID 29599478, double-blind crossover). Niacin: no RCT specifically testing it as an NAD+-elevation supplement was identified for this page; its NAD+-boosting role here rests on the mechanistic and microbial-conversion findings in Christen et al. 2026 (Human RCT, open-label) rather than a dedicated supplementation trial. The three-way comparison (Christen et al. 2026, PMID 41540253) is Human RCT but open-label, not double-blind.
The NMN and NR trials above enrolled different populations (postmenopausal prediabetic women vs healthy middle-aged/older adults of both sexes) over different durations (10 weeks vs 2×6 weeks) measuring different primary endpoints (insulin sensitivity vs NAD+ metabolome and tolerability). Their results are not a head-to-head comparison. The Christen et al. 2026 trial is the one study that dosed NR, NMN, and nicotinamide in the same 65 participants over the same 14 days — but it did not include niacin as a supplemented arm, and it was open-label rather than double-blind.
FAQ
Is there a real head-to-head human trial comparing NMN and NR?
Yes. Christen et al. 2026 (Nat Metab, PMID 41540253, NCT05517122) randomized 65 healthy participants to 14 days of NR, NMN, nicotinamide (Nam), or placebo, open-label. NR and NMN comparably increased circulatory NAD+ concentrations; nicotinamide produced only an acute, transient effect on the whole-blood NAD+ metabolome rather than the sustained increase seen with NR and NMN. The trial did not include niacin (nicotinic acid) as an arm.
Was the 2026 head-to-head trial double-blind?
No. Christen et al. 2026 describes itself as “a randomized, open-label, placebo-controlled study.” Participants and researchers knew which supplement each person received. This does not invalidate the NAD+-concentration measurements, which are objective lab values, but it is a different design from the double-blind NMN and NR trials cited elsewhere on this page.
What does the NMN human trial show?
Yoshino et al. 2021 (Science, PMID 33888596) randomized postmenopausal women with prediabetes who were overweight or obese to 10 weeks of oral NMN or placebo, double-blind. NMN increased insulin-stimulated glucose disposal (measured by hyperinsulinemic-euglycemic clamp) and skeletal-muscle insulin signaling; placebo produced no change. This is one trial in one population — it does not establish effects in men or in metabolically healthy adults.
What does the NR human trial show?
Martens et al. 2018 (Nat Commun, PMID 29599478) is a randomized, double-blind, placebo-controlled crossover trial (two 6-week periods) of NR in healthy middle-aged and older adults. NR was well tolerated and effectively raised NAD+ metabolism; the paper describes its blood-pressure and arterial-stiffness findings as preliminary, flagging them for confirmation in future trials rather than reporting them as established effects.
What causes the niacin flush?
Niacin (nicotinic acid) activates GPR109A receptors on skin cells, triggering prostaglandin release that dilates blood vessels — producing warmth, redness, and tingling, typically starting within 15–30 minutes of a dose. This is a well-characterized pharmacological effect of niacin, distinct from the NAD+-precursor trials cited above, neither of which reported flushing with NMN or NR.
References
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. https://pubmed.ncbi.nlm.nih.gov/29599478/
- Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026;8(1):62-73. https://pubmed.ncbi.nlm.nih.gov/41540253/
- Yang W, Huang J, Tang Z, Chen C, Sun Y. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients. 2026;18(14):2251. https://pubmed.ncbi.nlm.nih.gov/42514320/
Have a question about NMN vs NR vs Niacin — Trial Data? Send us an email